,Article Title,Author (only the last name),Year of publication,Reviewer,Inclusion Criteria,Exclusion Criteria,Which type of PD patients were included in the clustering analyses?,Genetic_Status_Informed,Were subtyped patients roughly at the same disease stage or duration?,Similar_PD_Staging,From how many different centers came the patients to be subtyped?,Multicentric_X_Others,How were patients recruited?,Recruitment_Community_or_Population,Which diagnostic criteria was utilized to diagnose PD?,Formal_Criteria_From_Mestre,Formal_Criteria_Utilized_or_Informed,Which was the sampling method?,Consecutive_or_Random_Sampling,Was there a longitudinal follow-up in any way?,Longitudinal_Followup_Time,Longitudinal_Followup_Status,"If longitudinal follow-up was provided, how much years were patients followed for?",Completeness of follow-up,Longitudinal_Folloup_Completion_Mestre_Definition,Longitudinal_Folloup_Years_Mestre_Definition,Completeness_of_Followup,Longitudinal_Followup_Years,Which type of descriptive data regarding the PD population was presented?,Minimum_Info_Complex_Data_Any_Present,Minimum_Info_Age_Sex_Staging_Scales_Medication,Minimum_Info_Age_Sex_Staging_Scales,Minimum_Info_Age_Sex_Staging,Minimum_Info_Age_Sex_OnsetAge,Minimum_Info_Age_Sex,Were the included patients for clustering purposes drug-naive?,Drug_Naive_Status,Number of PD patients utilized for clustering purposes,Number of PD patients utilized for validation purposes,Did the study include healthy controls in the clustering analyses alongside PD patients?,Number of healthy controls utilized for validation or technique elaboration purposes,Used_Controls_For_Comparisons,Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [AMP-PD],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [BioFIND],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Fox Insight],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [GP2 Dataset],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [LRRK2 Cohort Consortium],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Parkinson Progression Marker Initiative (PPMI)],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Parkinson's Disease Biomarker Program (PDBP)],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [UK Biobank],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Oxford Parkinson Disease Center Discovery Cohort],Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Other specific or local datasets],Performed_Validation,Validation_not_Perfored_X_same_Cohort_X_Different_Cohort,Validation_in_the_Same_Datasets_Sum,Validation_Datasets_Sum,Validation_in_a_Different_Cohort,Creation_Datasets_Sum,"If a different publicly available dataset than the ones mentioned above was utlized for any means, please specify its full name",From which countries or world region came the patients whose data was used in the clustering?,Which type data was utilized for the clustering algorithm?,Treatment_Response_Evaluated,"Which type data was evaluated for association / interpretation purposes of the identified clusters, indepentently if they were significant or not?",If the paper contains multiple exploration of clusters (creates different subgroups multiple times) shortly describe the differences in the cluster strategy for each exploration:,"If clinical data obtained from rating scales was used for clustering purposes, which data and rating scales were utilized?","If neuroimaging data was utilized for clustering, did the article perform any sort of quality control measure?","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [MRI cortical thickness]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [MRI subcortical volume]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [MRI white matter lesions / hyperintensities]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [Functional MRI]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [MRI Others]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [PET]","If neuroimaging data was utilized for clustering or interpretation / association  purposes, which ones were utilized? [SPECT DAT binding ratios]",How many subtypes did the evaluated study identified?,"If they were identified, what are the names (meaning) of the identified clusters?",What is the number of patients present in each of the identified clusters?,Subtype stability,Did the article provide an individual level prediction algorithm?,Number of PD patients utilized for clustering purposes for bubble,None of the mentioned data on the PD population was informed by the study,Age,Gender,Ethnicity,Education,Income,Family History,Age at disease onset,Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales),"Vital Signs (blood pressure, cardiac frequency)","Physical Attributes (weight, height etc)",Medication Doses,"Genetic Status (monogenic PD, polygenic risk score)","Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",Summarised data from neuroimaging studies (such as cortical thickness),Biomarker's profile (results from biomarker tests),UK Brain Bank Criteria,MDS Clinical Criteria,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),Clinical Diagnosis (no specific criteria mentioned - PDBP),Douglas Criteria,World Health Organization Criteria,ICD-10 Criteria,Postmortem pathological diagnosis (part of the sample),Postmortem pathological diagnosis (complete sample),Self Report,Other criteria,Not sure or clearly stated,Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [AMP-PD],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [BioFIND],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Fox Insight],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [GP2 Dataset],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [LRRK2 Cohort Consortium],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Parkinson Progression Marker Initiative (PPMI)],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Parkinson's Disease Biomarker Program (PDBP)],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [UK Biobank],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Oxford Parkinson Disease Center Discovery Cohort],Dataset_Used Which datasets were utilized in the creation and/or validation of the subtyping algorithm? [Other specific or local datasets],Open_Datasets_Used_Sum,Open_Datasets_Used_Yes_or_No,Sub-Saharan Africa_Adjusted_PPMI,Middle East & North Africa_Adjusted_PPMI,"East Asia & Pacific (China, Japan, Australia)_Adjusted_PPMI","South Asia (India, Pakistan, Bangladesh)_Adjusted_PPMI",Europe & Central Asia_Adjusted_PPMI,Latin America & the Caribbean_Adjusted_PPMI,North America_Adjusted_PPMI,Original country without Sub-Saharan Africa and Middle East & North Africa,Sub-Saharan Africa,Middle East & North Africa,"East Asia & Pacific (China, Japan, Australia)","South Asia (India, Pakistan, Bangladesh)",Europe & Central Asia,Latin America & the Caribbean,North America
0,A Data-Driven Approach to the Study of Heterogeneity in Idiopathic Parkinson's Disease: Identification of Three Distinct Subtypes,Graham,1999,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses",0,0,0,1,0,1,No,0.0,176,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",,"Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, Beck Depression Inventory (BDI), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,5,Group 1; Group 2; Group 3; Group 4; Group 5,60; 37; 37; 23; 19,Unknown,No or not sure,176,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
1,A Hybrid Machine Learning and Network Analysis Approach Reveals Two Parkinson's Disease Subtypes from 115 RNA-Seq Post-Mortem Brain Samples,Termine,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Not sure or clearly stated,0,Postmortem pathological diagnosis (complete sample),2,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,Age,0,0,0,0,0,0,Not sure or clearly stated,0.0,115,No validation was performed,Yes,95,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Europe & Central Asia, North America",Omics - Transcriptomics,0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Omics - Transcriptomics",,No clinical scales or data were utilized for the subtyping of this article,No neuroimaging data was utilized for clustering purposes,,,,,,,,2,PDC1; PDC2,50; 65,Unknown,No or not sure,115,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,"Europe & Central Asia, North America",0,0,0,0,1,0,1
2,ADCoC: Adaptive Distribution Modeling Based Collaborative Clustering for Disentangling Disease Heterogeneity from Neuroimaging Data,Liu,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,170,No validation was performed,Yes,77,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America",Neuroimaging - Structural or Volumetric MRI,0.0,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",,No clinical scales or data were utilized for the subtyping of this article,Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,Clustering,"Clustering, Interpretation / Association",,,,,,2,P1; P2,CHECK,Unknown,No or not sure,170,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
3,Agglomerative and divisive hierarchical Bayesian clustering,Burghardt,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,3,The study was cross-sectional or did not inform the follow-up period,0,2,,3.0,"Age, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Biomarker's profile (results from biomarker tests)",1,0,0,0,0,0,Yes,1.0,243,No validation was performed,No,,1,,,,,,"Creation, Validation",,,,,1,1,1,1,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Age, Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc)",0.0,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Neuroimaging - DaTSCAN",,"Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA)",No neuroimaging data was utilized for clustering purposes,,,,,,,Interpretation / Association,3,Green; Purple; Yellow,57; 84; 102,Unknown,No or not sure,243,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
4,Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach,Starkstein,2014,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Income, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,Not sure or clearly stated,0.0,342,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Europe & Central Asia, North America","Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Medication (types and/or dosages)",,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age at onset or diagnosis, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,"No Anxiety, No Depression; Persistente Anxiety with Depression; Episodic Anxiety, No Depression; Persistent and Episodic Anxiety with Depression",215; 47; 40; 36,Unknown,No or not sure,342,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,"Europe & Central Asia, North America",0,0,0,0,1,0,1
5,Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories,Birkenbihl,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,The study was cross-sectional or did not inform the follow-up period,0,2,,5.0,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,407,No validation was performed,No,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - DaTSCAN, Omics - Transcriptomics, Omics - Genomics",,"MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Slow; Moderate; Fast,124; 230; 53,Stable,No or not sure,407,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
6,Assessing Parkinson's disease speech signal generalization of clustering results across three countries,Tsanas,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,Self Report,0,0,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender",0,0,0,0,0,1,Not sure or clearly stated,0.0,1530,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Europe & Central Asia, North America",Clinical - Phonation,0.0,The study did not provide association / interpretation analyses,,No clinical scales or data were utilized for the subtyping of this article,No neuroimaging data was utilized for clustering purposes,,,,,,,,4,The article didn't provide clusters or names for the clusters obtained,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Unknown,No or not sure,1530,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,"Europe & Central Asia, North America",0,0,0,0,1,0,1
7,Association between Cognitive Impairment and Freezing of Gait in Patients with Parkinson's Disease,Gan,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,PD with specific or special features (either Sporadic / Idiopathic or Monogenic),0,No,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,41,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",,"Montreal Cognitive Assessment (MoCA), Frontal Assessment Battery (FAB), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,2,Cluster 1; Cluster 2,13; 28,Unknown,No or not sure,41,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
8,Bayesian Longitudinal Modeling of Early Stage Parkinson's Disease Using DaTscan Images,Zhou,2019,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,Not clearly stated,0,2,,5.0,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,365,365,No,,1,,,,,,"Creation, Validation",,,,,1,1,1,1,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America",Neuroimaging - DaTSCAN,0.0,Neuroimaging - DaTSCAN,,No clinical scales or data were utilized for the subtyping of this article,Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,,,,"Clustering, Interpretation / Association",4,The article didn't provide clusters or names for the clusters obtained,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Stable,No or not sure,365,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
9,Biomarker characterization of clinical subtypes of Parkinson Disease,Deng,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,1,Yes,1.0,More than one center,1.0,Clinics or research institutions,0,Other criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Ethnicity, Education, Age at disease onset, Vital Signs (blood pressure, cardiac frequency), Physical Attributes (weight, height etc), Medication Doses, Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Biomarker's profile (results from biomarker tests)",1,0,0,0,1,1,Not sure or clearly stated,0.0,206,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,Early Parkinson's disease Longitudinal Singapore (PALS),"East Asia & Pacific (China, Japan, Australia)","Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Omics - Genomics",0.0,"Clinical - Gender, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Omics - Genomics",,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age at onset or diagnosis, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Hospital Anxiety and Depression Scale (HADS), RBD Single Question Screen(RBD1Q), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,A;B;C,43;98;65,Unknown,No or not sure,206,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
10,Blood Biomarkers With Parkinson's Disease Clusters and Prognosis: The Oxford Discovery Cohort,Lawton,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,3.2,0.88,2,2,0.88,3.2,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Biomarker's profile (results from biomarker tests)",1,1,1,1,1,1,No,0.0,621,No validation was performed,No,,1,,,,,,,,,Creation,,0,0,0,0,0,1,Oxford Parkinson's Disease Centre Discovery cohort study,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), clinical: non motor symptoms (MDS-UPDRS I and II)",0.0,"Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc)",,"MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,Cluster 1; Cluster 2; Cluster 3; Cluster 4,210; 104; 152; 155,Stable,No or not sure,621,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
11,Can We Predict the Motor Performance of Patients With Parkinson's Disease Based on Their Symptomatology?,Lebel,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Physical Attributes (weight, height etc), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,115,No validation was performed,Yes,69,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,Quebec Parkinson Network and the Movement Disorders Clinic of the University of Calgary,North America,Clinical - Motor Tests (example: Timed-Up & Go),0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Medication (types and/or dosages), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations)",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Physical attributes (weight, height), Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, Mini-Mental State Examination (MMSE)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,Cluster 1; Cluster 2; Cluster 3; Cluster 4,36; 38; 21; 20,Unknown,No or not sure,115,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
12,Characterization of idiopathic Parkinson's disease subgroups using quantitative gait analysis and corresponding subregional striatal uptake visualized using 18F-FP-CIT positron emission tomography,Kim,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Not sure or clearly stated,0.0,Not sure or clearly stated,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Physical Attributes (weight, height etc), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Summarised data from neuroimaging studies (such as cortical thickness)",1,0,1,1,0,1,Not sure or clearly stated,0.0,88,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Other Methods (e.g. neuromelanin-sensitive MRI)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Neuroimaging - Other Methods (e.g. neuromelanin-sensitive MRI)",,"Patient's age, Physical attributes (weight, height), UPDRS motor scores, UPDRS non-motor scores, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,,,Interpretation / Association,,4,The article didn't provide clusters or names for the clusters obtained,12; 23; 16; 37,Unknown,No or not sure,88,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
13,Characterization of Parkinson's Disease Subtypes and Related Attributes,Shakya,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,3,0.9583,2,2,0.9583,3.0,Gender,0,0,0,0,0,0,Yes,1.0,408,No validation was performed,No,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Gender, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - DaTSCAN",,"Patient's age at onset or diagnosis, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), SCOPA-AUT, Geriatric Depression Scale (GDS), State-Trait Anxiety Inventory (STAI), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ)",Neuroimaging data was utilized for clustering purposes but do they do not require quality control (example: DATScan),,,,,,,Interpretation / Association,2,Mild motor and non-motor subtype; Severe motor and non-motor subtype,269; 138,Stable,No or not sure,408,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
14,Classification of l-DOPA pharmacokinetics shapes and creating a predictive model,Nishikawa,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Not sure or clearly stated,0.0,Not sure or clearly stated,0,MDS Clinical Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,No,0.0,270,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age, Clinical - Gender, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), Physical attributes (weight, height), Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,group 1; group 2; group 3,129; 97; 44,Unknown,No or not sure,270,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
15,Clinical heterogeneity in newly diagnosed Parkinson's disease,Post,2008,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Not sure or clearly stated,0,Douglas Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,No,0.0,131,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",Multiple explorations with same features using 2 or 3 clusters strategies.,"Patient's age, UPDRS motor scores, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, Mini-Mental State Examination (MMSE), Hospital Anxiety and Depression Scale (HADS)",No neuroimaging data was utilized for clustering purposes,,,,,,,,,two-cluster (younger onset; older onset);  three-cluster (younger onset; intermediate older onset; older onset),two-cluster (73; 58); three-cluster (44; 35; 52),Unknown,No or not sure,131,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
16,Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis,Liu,2011,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,138,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)","K-means cluster analysis was performed on the subjects with the five-, four-, and three-cluster solutions, using the standardized scores of the clinical variables to indentify the clinical heterogeneity of subjects with early-stage PD. ","Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Pittsburgh Sleep Quality Index (PSQI), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,5,Three-cluster solution: YO; TD; RDP / Four-cluster solution: YO; TD; RDP; NTD / Five-cluster solution: Cluster 1; Cluster 2; Cluster 3; Cluster 4; Cluster 5,Three-cluster solution: 53; 64; 21 / Four-cluster solution: 50; 53; 7; 28 / Five-cluster solution: 28; 7; 50; 52; 1,Unknown,No or not sure,138,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
17,Clinical Subtypes of Parkinson's Disease,van Rooden,2011,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,1,The study was cross-sectional or did not inform the follow-up period,0,0,,1.0,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,344,357,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,Clustering: PROPARK | Validation: ELEP,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, SCOPA-COG, SCOPA-AUT, SCOPA-Motor, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Beck Depression Inventory (BDI), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,Cluster 1; Cluster 2; Cluster 3; Cluster 4,169; 45; 104; 26,Unknown,No or not sure,344,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
18,Clinically relevant connectivity features define three subtypes of Parkinson's disease patients,Guo,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,134,98,Yes,77,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)",Neuroimaging - Diffusion Imaging MRI,0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Neuroimaging - Other Methods (e.g. neuromelanin-sensitive MRI)",,"Patient's sex, Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, MDS-UPDRS Part III, Mini-Mental State Examination (MMSE), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Epworth Sleepiness Scale (ESS), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,"Clustering, Interpretation / Association","Clustering, Interpretation / Association",,,3,severe depression-dominant; severe motor-dominant; mild,53; 37; 44,Unknown,No or not sure,134,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
19,Cluster Analysis of Categorical Variables of Parkinson's Disease Patients,Hendricks,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Family History, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,Yes,1.0,423,No validation was performed,No,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Other (pain, fatigue etc)",0.0,The study did not provide association / interpretation analyses,,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, UPDRS motor scores",No neuroimaging data was utilized for clustering purposes,,,,,,,,47,#1; #2; #3; #4; #5; #6; #7; #8; #9; #10; #11; #12; #13; #14; #15; #16; #17; #18; #19; #20; #21; #22; #23; #24; #25; #26; #27; #28; #29; #30; #31; #32; #33; #34; #35; #36; #37; #38; #39; #40; #41; #42; #43; #44; #45; #46; #47,1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 1; 2; 2; 3; 3; 3; 3; 3; 3; 3; 3; 4; 4; 4; 4; 4; 6; 7; 7; 7; 7; 7; 9; 9; 9; 10; 11; 12; 14; 14; 16; 17; 19; 21; 21; 33; 38; 66,Unknown,No or not sure,423,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
20,Cluster analysis of cognitive performance in a sample of patients with Parkinson's disease,Souza,2016,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,Not sure or clearly stated,0.0,100,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Latin America & the Caribbean,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",,"Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), Frontal Assessment Battery (FAB), Digit Span Tests (backward and/or symbol span), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cluster 1; Cluster 2; Cluster 3,38; 42; 14,Unknown,No or not sure,100,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,Latin America & the Caribbean,0,0,0,0,0,1,0
21,Clustering of Alzheimer's and Parkinson's disease based on genetic burden of shared molecular mechanisms,Emon,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,"The study did provide a follow-up, but did not report this data",The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,1,Yes,1.0,358,303,Yes,198,1,,,,,,"Creation, Validation",,,,"Creation, Validation",1,1,1,2,0,2,CLUSTERING: ADNI (Alzheimer's) | VALIDATION:  ADNI (Alzheimer's); ROSMAP (AD); IDIBAPS (AD]; AETIONOMY PD; ICEBERG; DIGPD,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America",Omics - Genomics,0.0,"Clinical - Age, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN, Omics - Transcriptomics, Omics - Other (e.g. metabolomics, metagenomics), methylomics",Validates in a merged dataset ADNI+PPMI and also in independent datasets (AETIONOMY PD+DIGPD+ICEBERG),No clinical scales or data were utilized for the subtyping of this article,No neuroimaging data was utilized for clustering purposes,Interpretation / Association,Interpretation / Association,,,,,Interpretation / Association,4,"AKT1;  IL1B, NLRP3, TP53; MTHFR; MAPK9",There are 4 clusters for 4 PD datasets,Unknown,No or not sure,358,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
22,Clustering of Parkinson subtypes reveals strong influence of DRD2 polymorphism and gender,Pelzer,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,1,Yes,1.0,Single center,0.0,Clinics or research institutions,0,Other criteria,1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",1,0,1,1,1,1,No,0.0,91,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Gender, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Medication (types and/or dosages), Omics - Genomics",0.0,"Clinical - Gender, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age at onset or diagnosis, MDS-UPDRS Part III",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cluster 1; Cluster 2; Cluster 3,26; 34; 31,Unknown,No or not sure,91,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
23,Clustering Parkinson's and Age-Related Voice Impairment Signal Features for Unsupervised Learning,Rueda,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Not sure or clearly stated,0.0,Not sure or clearly stated,0,Not sure or clearly stated,0,0,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender",0,0,0,0,0,1,No,0.0,57,No validation was performed,Yes,57,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,Clinical - Phonation,0.0,The study did not provide association / interpretation analyses,"This study uses five hierarchical and one partitioning clustering methods. Hierarchical clustering methods include HierarchicalK-Means (HKMeans) , Hierarchical Cluster (HCluster), Agglomerative Nesting (AGNES), Divisive Analysis (DIANA), and Self-Organizing Tree Algorithm (SOTA).",MDS-UPDRS Part III,No neuroimaging data was utilized for clustering purposes,,,,,,,,5,0; 1; 2; 3; 4,3; 82; 22; 2; 5,Unknown,No or not sure,57,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
24,Cognitive Characteristics Associated with Mild Cognitive Impairment in Parkinson's Disease,McKinlay,2009,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales)",0,0,0,0,0,0,No,0.0,40,No validation was performed,No,40,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",,No clinical scales or data were utilized for the subtyping of this article,No neuroimaging data was utilized for clustering purposes,,,,,,,,3,NCI; UCI; MCI,19; 9; 12,Unknown,No or not sure,40,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
25,Cognitive phenotypes in Parkinson's disease: A latent profile analysis,Barvas,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,65,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",,"Semantic Fluency Test (e.g. fruits, objects, names etc), Rey-Osterrieth Complex Figure Test (ROCF), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cluster A; Cluster B; Cluster C,14; 35; 16,Unknown,No or not sure,65,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
26,Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach,Liepelt-Scarfone,2012,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,PD with specific or special features (either Sporadic / Idiopathic or Monogenic),0,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,121,97,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Quality of Life, Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Beck Depression Inventory (BDI), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,2,Cluster-I; Cluster-II,50; 71,Unknown,No or not sure,121,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
27,Comprehensive subtyping of Parkinson's disease patients with similarity fusion: a case study with BioFIND data,Brendel,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,1,No,0.0,More than one center,1.0,Community or population based,1,UK Brain Bank Criteria,1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Ethnicity, Education, Family History, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Biomarker's profile (results from biomarker tests)",1,1,1,1,0,1,No,0.0,103,No validation was performed,No,,1,,Creation,,,,,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,"Clinical - Age, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Omics - Genomics",,"Patient's sex, Patient's age, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Montreal Cognitive Assessment (MoCA), The Schwab and England ADL (Activities of Daily Living) scale, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Subtype I; Subtype II; Subtype III,60; 20; 23,Unknown,No or not sure,103,0,1,1,1,1,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
28,"Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson's disease",Diez-Cirarda,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,No,0.0,99,No validation was performed,No,62,1,,,,,,,,,,Creation,0,0,0,0,0,1,Biocruces Bizkaia Health Research Institute; University of Deusto; Centre for Addiction and Mental Health,"Europe & Central Asia, North America","Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Neuroimaging - Functional MRI",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Geriatric Depression Scale (GDS), Beck Depression Inventory (BDI), Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage",Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,,,,Interpretation / Association,,,,3,mild; depression dominant; cognitive dominant,42; 36; 21,Unknown,No or not sure,99,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,"Europe & Central Asia, North America",0,0,0,0,1,0,1
29,Cortical atrophy patterns in early Parkinson's disease patients using hierarchical cluster analysis,Uribe,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Summarised data from neuroimaging studies (such as cortical thickness)",1,0,1,1,1,1,Yes,1.0,77,No validation was performed,Yes,50,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America",Neuroimaging - Structural or Volumetric MRI,0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Neuroimaging - Structural or Volumetric MRI",,"Patient's sex, Patient's age, UPDRS motor scores, MDS-UPDRS Part II, MDS-UPDRS Part III, University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Hopkins Verbal Learning Test (HTLV), Symbol Digit Modalities Test, The Schwab and England ADL (Activities of Daily Living) scale, Geriatric Depression Scale (GDS), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,"Clustering, Interpretation / Association",,,,,,,2,The article didn't provide clusters or names for the clusters obtained,33; 44,Unknown,No or not sure,77,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
30,Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study,Zhang,2019,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,1,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,6,The study was cross-sectional or did not inform the follow-up period,0,2,,6.0,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Summarised data from neuroimaging studies (such as cortical thickness)",1,1,1,1,0,1,Yes,1.0,466,No validation was performed,Yes,217,1,,,,,,"Creation, Validation",,,,,1,1,1,1,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - DaTSCAN",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - DaTSCAN",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Judgment of Line Orientation Test, Symbol Digit Modalities Test, SCOPA-AUT, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Geriatric Depression Scale (GDS)",Neuroimaging data was utilized for clustering purposes but do they do not require quality control (example: DATScan),,,,,,,"Clustering, Interpretation / Association",3,"Mild Baseline, Moderate Motor Progression; Moderate Baseline, Mild Progression;  Severe Baseline, Rapid Progression;",201; 107; 158,Stable,No or not sure,466,0,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
31,Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort,Chen,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,"UK Brain Bank Criteria, MDS Clinical Criteria",1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,"The study did provide a follow-up, but did not report this data",The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,Not sure or clearly stated,0.0,114,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Age, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Polyneuropathy",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",,"Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Non-Motor Symptoms Questionnaire (NMSQ), Montreal Cognitive Assessment (MoCA), SCOPA-AUT, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Subtype I; Subtype II; Subtype III,40; 49; 25,Unknown,No or not sure,114,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
32,"Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden",Eglit,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,No,0.0,157,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,"Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Age, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",,CHECK,No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Non-apathetic;  Low interest/Energy; Low initiation,48; 76; 33,Unknown,No or not sure,157,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
33,Developing and validating Parkinson's disease subtypes and their motor and cognitive progression,Lawton,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,3,0.86,2,2,0.86,3.0,"Gender, Ethnicity, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,1601,944,No,,1,,,,,,,,,Validation,Creation,1,2,0,1,1,1,CLUSTERING: Tracking Parkinson's; Oxford Parkinson Disease Center Discovery cohort | VALIDATION: Oxford Parkinson Disease Center Discovery cohort,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Other (pain, fatigue etc)",1.0,"Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Omics - Genomics, Clinical - Medication Response",The study did not provide this type of information,"Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), MDS-UPDRS Part I, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,"fast motor progression; mild motor and non-motor disease; severe motor disease, poor psychological well-being and poor sleep;  slow motor progression","493, 459, 336, 313 | 307, 167, 223, 247",Unknown,No or not sure,1601,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
34,Differences in cognitive performance in nondemented Parkinson's disease: A latent profile analysis of cognitive subtypes,Alonso-Recio,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,Other criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,71,No validation was performed,Yes,51,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Quality of Life",,"Semantic Fluency Test (e.g. fruits, objects, names etc), Digit Span Tests (backward and/or symbol span), Boston Naming Test (BNT), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,executive dysfunction; memory and executive dysfunction; memory dysfunction; noncognitive dysfunction,23; 20; 17; 11,Unknown,No or not sure,71,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
35,Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease,Kawabata,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,No,0.0,44,No validation was performed,No,24,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Functional MRI",,Other clinical scales (not present in this form),No neuroimaging data was utilized for clustering purposes,Interpretation / Association,,,Interpretation / Association,,,,3,Parkinson's disease with amnestic cognitive deficits (PD-A); Parkinson's disease  with non-amnestic cognitive deficits (PD-NA),20; 24,Unknown,No or not sure,44,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
36,Essential tremor-Parkinson's disease syndrome: clinical characteristics and subtypes using cluster analysis,Hou,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,PD with specific or special features (either Sporadic / Idiopathic or Monogenic),0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,"UK Brain Bank Criteria, Clinical Diagnosis (no specific criteria mentioned - PDBP)",1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Family History, Vital Signs (blood pressure, cardiac frequency), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,1,Yes,1.0,93,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Family history",,"UPDRS motor scores, Non-Motor Symptoms Scale (NNMS), Montreal Cognitive Assessment (MoCA), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,2,ET-PD cluster 1; ET-PD cluster 2; PD,34; 59,Unknown,No or not sure,93,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
37,Evidence for subtypes of freezing of gait in Parkinson's disease,Martens,2018,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,PD with specific or special features (either Sporadic / Idiopathic or Monogenic),0,No,0.0,Single center,0.0,Not sure or clearly stated,0,Not sure or clearly stated,0,0,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,No,0.0,41,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)",Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture),0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",,"UPDRS motor scores, Mini-Mental State Examination (MMSE), Additional clinical scales not listed here were utilized, Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Asymmetric-Motor; Anxious; Sensory-Attention,13; 15; 13,Unknown,No or not sure,41,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
38,Feature selection and machine learning methods for optimal identification and prediction of subtypes in Parkinson's disease,Salmanpour,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,4,The study was cross-sectional or did not inform the follow-up period,0,2,,4.0,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,885,885,No,,1,,,,,,"Creation, Validation",,,,,1,1,1,1,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Anosmia or Hyposmia, Clinical - Other (pain, fatigue etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN, Neuroimaging - Radiomics, Omics - Genomics",0.0,The study did not provide association / interpretation analyses,"It employed multiple strategies and compared among them. In the first part, they employed FSAs to rank features prior to application of clustering: the most optimal combination was obtained via the HMLSs: UDFSA + KMA as well as FSASL + KMA.  They employed multiple Classifier algorithms (CA). Overall, they conclude that combining non-imaging information with SPECT-based radiomics features, and optimal utilization of HMLSs, can robustly identify subtypes in PD and enable appropriate outcome prediction in PD patients.","Additional clinical scales not listed here were utilized, Patient's sex, Patient's age, Ethnicity, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), Physical attributes (weight, height), MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Symbol Digit Modalities Test, SCOPA-AUT, REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), RBD Single Question Screen(RBD1Q), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,,,,Clustering,3,The article didn't provide clusters or names for the clusters obtained,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Unknown,No or not sure,885,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
39,Fine Motor Assessment With Unsupervised Learning For Personalized Rehabilitation in Parkinson Disease,Rovini,2019,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,Not sure or clearly stated,0,0,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender",0,0,0,0,0,1,No,0.0,30,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia)",0.0,The study did not provide association / interpretation analyses,,MDS-UPDRS Part III,No neuroimaging data was utilized for clustering purposes,,,,,,,,3,CHECK,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Unknown,No or not sure,30,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
40,Free Water Fraction Predicts Cognitive Decline for Individuals with Idiopathic Parkinson's disease,Crowley,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,"The study did provide a follow-up, but did not report this data",The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,No,0.0,112,56,Yes,62,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,Neuroimaging - Diffusion Imaging MRI,0.0,"Clinical - Age, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",CHECK,No clinical scales or data were utilized for the subtyping of this article,Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,"Clustering, Interpretation / Association",Clustering,,,3,Low FWF; Medium FWF; High FWF,36; 57; 19,Unknown,No or not sure,112,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
41,Heterogeneity among patients with Parkinson's disease: cluster analysis and genetic association,Ma,2015,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Monogenic and Sporadic / Idiopathic,1,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",1,0,1,1,1,1,No,0.0,1510,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,Chinese National Consortium on Neurodegenerative Diseases,"East Asia & Pacific (China, Japan, Australia)","Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Omics - Genomics",,"Patient's sex, Patient's age, UPDRS motor scores, Mini-Mental State Examination (MMSE), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Pittsburgh Sleep Quality Index (PSQI), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,"Non-tremor dominant, NTD; (rapid disease progression with late onset, RDP-LO; benign pure motor, BPM; tremor dominant with slow progression, TD-SP ",469; 67; 778; 196,Unknown,No or not sure,1510,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
42,Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach,Lewis,2005,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Family History, Disease duration, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses",0,0,0,1,0,1,No,0.0,120,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",The study did not provide this type of information,"Patient's age at onset or diagnosis, MDS-UPDRS Part III, Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,younger disease onset; tremor dominant; non-tremor dominant with cognitive impairment and mild depression; rapid disease progression but no cognitive impairment,49; 20; 20; 31,Unknown,No or not sure,120,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
43,Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson's disease,Inguanzo,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,No,0.0,62,No validation was performed,Yes,33,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Diffusion Imaging MRI",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Medication (types and/or dosages), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Diffusion Imaging MRI",,No clinical scales or data were utilized for the subtyping of this article,Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,"Clustering, Interpretation / Association","Clustering, Interpretation / Association",,,"Clustering, Interpretation / Association",,,3,PD1; PD2; PD3,15; 21; 26,Unknown,No or not sure,62,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
44,Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts,Dado,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,"Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI), Clinical Diagnosis (no specific criteria mentioned - PDBP)",1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,1,2,2,1.0,5.0,"Age, Gender",0,0,0,0,0,1,Yes,1.0,294,263,Yes,154,1,,,,,,Creation,Validation,,,,1,2,0,1,1,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Omics - Genomics",,"MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Hopkins Verbal Learning Test (HTLV), Judgment of Line Orientation Test, Wechsler Adult Intelligence Scale III (WAIS-III), Symbol Digit Modalities Test, SCOPA-AUT, Geriatric Depression Scale (GDS), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,PDvec1; PDvec2; PDvec3,134; 114; 46,Stable,No or not sure,294,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
45,Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography,Yassine,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,0.83,2,2,0.83,5.0,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,44,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,Neurophysiology - Electroencephalography,0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, MDS-UPDRS Part II, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), Boston Naming Test (BNT), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,G1 moderate with rapid motor deterioration; G2 moderate; G3 mild to severe,9; 22; 13,Stable,No or not sure,44,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
46,Identifying and validating subtypes of Parkinson's disease based on multimodal MRI data via hierarchical clustering analysis,Cao,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,No,0.0,86,No validation was performed,No,44,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Functional MRI",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Functional MRI",,"Patient's sex, Patient's age, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,Clustering,Clustering,,"Clustering, Interpretation / Association",,,,2,Cluster1; Cluster 2,51; 35,Unknown,No or not sure,86,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
47,Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering,Rodriguez-Sanchez,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,MDS Clinical Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,402,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Medication (types and/or dosages), disease duration, ",Partition A (ICRDs-PIGD); Partition B (apathy-cognitive-pain-gastrointestinal-sleep-urinary); Partition C (dyskinesias-psychosis);  Partition D (mental fatigue-physical fatigue); Partition E (axial symptoms-bradykinesia-loss of smell-motor fluctuations); Partition F (orthostatic hypotension-sexual problems); Partition G (weight loss-depression); Partition H (excessive sweating-anxiety),"Patient's sex, Patient's age, Patient's age at onset or diagnosis, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr)",No neuroimaging data was utilized for clustering purposes,,,,,,,,,Partition A: Subtype A1; Subtype A2 | Partition B: Subtype B1; Subtype B2 | Partition C: Subtype C1; Subtype C2;  Subtype C3 | Partition D: Subtype D1; Subtype D2 | Partition E: Subtype E1; Subtype E2 | Partition F: Subtype F1; Subtype F2 | Partition G: Subtype G1;Subtype G2 | Partition H: Subtype H1; Subtype H2,355; 67; 199; 203; 242; 112; 48; 272; 130; 199; 203; 214; 188; 317; 85; 299; 103,Unknown,No or not sure,402,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,"Europe & Central Asia, North America",0,0,0,0,1,0,1
48,Identifying subtypes of mild cognitive impairment in Parkinson's disease using cluster analysis,Pourzinal,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,85,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",Several models were generated and contrasted to determine the most appropriate structure for the dataset -> four-cluster model appeared to be the most appropriate,"Hopkins Verbal Learning Test (HTLV), Benton Visual Retention Test (BVRT), Boston Naming Test (BNT), MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Montreal Cognitive Assessment (MoCA), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,(1) frontal-dominant impairment; (2) posterior-cortical-dominant impairment; (3) global impairment; (4) cognitively intact,36; 18; 24; 7,Unknown,No or not sure,85,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
49,Identifying subtypes of treatment effects of subthalamic nucleus deep brain stimulation on motor symptoms in patients of late-stage Parkinson's disease with cluster analysis,Chen,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,MDS Clinical Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,1,The study was cross-sectional or did not inform the follow-up period,0,1,,1.0,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,No,0.0,28,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Age, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Medication (types and/or dosages)",,"Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,high response; low response; moderate response with fast progression,4; 17; 7,Unknown,No or not sure,28,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
50,Identifying the Clusters within Nonmotor Manifestations in Early Parkinson's Disease by Using Unsupervised Cluster Analysis,Yang,2014,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,56,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,The study did not provide association / interpretation analyses,,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,The article didn't provide clusters or names for the clusters obtained,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Unknown,No or not sure,56,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
51,Longitudinal clustering analysis and prediction of Parkinson's disease progression using radiomics and hybrid machine learning,Salmanpour,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,4,1,2,2,1.0,4.0,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,143,No validation was performed,No,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Neuroimaging - DaTSCAN, Neuroimaging - Radiomics",0.0,The study did not provide association / interpretation analyses,,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Ethnicity, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Hopkins Verbal Learning Test (HTLV), Judgment of Line Orientation Test, Digit Span Tests (backward and/or symbol span), Symbol Digit Modalities Test, Benton Visual Retention Test (BVRT), SCOPA-COG, SCOPA-AUT, SCOPA-Motor, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Geriatric Depression Scale (GDS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), RBD Single Question Screen(RBD1Q), Epworth Sleepiness Scale (ESS), Parkinson's Disease Questionnaire 8 Items (PDQ8)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,,,,Clustering,,Clustering,3,The article didn't provide clusters or names for the clusters obtained,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Stable,No or not sure,143,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
52,Longitudinal follow up of data-driven cognitive subtypes in Parkinson's disease,Pourzinal,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,Not sure or clearly stated,0,0,Not sure or clearly stated,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,4.87,0.3411,0,2,0.3411,4.87,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,85,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",,"Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Posterior-cortical; Globally impaired; Cognitively intact,12; 4; 13,Unknown,No or not sure,85,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
53,Mapping Actuarial Criteria for Parkinson's Disease-Mild Cognitive Impairment onto Data-Driven Cognitive Phenotypes,Kenney,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Ethnicity, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,No,0.0,494,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",,"Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Judgment of Line Orientation Test, Wechsler Adult Intelligence Scale III (WAIS-III), Boston Naming Test (BNT), Other clinical scales (not present in this form), UPDRS motor scores",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cognitively average; Low executive function; Prominently impaired executive function and memory,154; 227; 113,Unknown,No or not sure,494,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
54,"Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment",Siciliano,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Not sure or clearly stated,0,MDS Clinical Criteria,1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,Yes,1.0,82,No validation was performed,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Neuroimaging - Structural or Volumetric MRI",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Digit Span Tests (backward and/or symbol span), Beck Depression Inventory (BDI), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,Interpretation,,,,,,,3,The article didn't provide clusters or names for the clusters obtained,54; 19; 9,Unknown,No or not sure,82,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
55,Motor subtype changes in early Parkinson's disease,Eisinger,2017,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,7.84,1,2,2,1.0,7.84,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,423,No validation was performed,No,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech)",0.0,The study did not provide association / interpretation analyses,,"MDS-UPDRS Part II, MDS-UPDRS Part III",No neuroimaging data was utilized for clustering purposes,,,,,,,,5,Tremor Dominant (TD); Axial Dominant; Appendicular Dominant; Rigidity Dominant; Postural and Instability Gait Disorder Dominant,"The article didn't provide clusters, names or numbers of patients in the clusters obtained",Stable,No or not sure,423,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
56,Multi-layer Trajectory Clustering: a Network Algorithm for Disease Subtyping,Krishnagopal,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,1,2,2,1.0,5.0,"Age, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,No,0.0,194,No validation was performed,Not sure or clearly stated,,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Age, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",Multi-layer Trajectory Clustering -  ranges of independent outcome variable (representative of disease severity),"Patient's sex, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Symbol Digit Modalities Test, SCOPA-AUT, The Schwab and England ADL (Activities of Daily Living) scale, REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,S0 (green); S1 (orange); S2 (red); S3 (blue),47; 44; 58; 48,Stable,No or not sure,194,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
57,Multimodal phenotypic axes of Parkinson's disease,Markello,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,"The study did provide a follow-up, but did not report this data",The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,186,No validation was performed,No,87,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN",0.0,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN","Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN","Patient's sex, Patient's age, Patient's age at onset or diagnosis, Ethnicity, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Symbol Digit Modalities Test, SCOPA-AUT, Geriatric Depression Scale (GDS), State-Trait Anxiety Inventory (STAI), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,"Clustering, Interpretation / Association","Clustering, Interpretation / Association",,,,,"Clustering, Interpretation / Association",3,Mild; intermediate; severe,72; 69; 45,Unknown,No or not sure,186,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
58,Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis,Brennan,2017,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,Not sure or clearly stated,0,0,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,199,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,University of Pennsylvania Udall Center of Excellence in Parkinson's Disease Research,North America,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech) Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, Montreal Cognitive Assessment (MoCA), The Schwab and England ADL (Activities of Daily Living) scale, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Geriatric Depression Scale (GDS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,intact cognition group; amnestic group; mixed impairment group,109; 64; 26,Unknown,No or not sure,199,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
59,New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes,Fereshtehnejad,2015,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,4.5,0.629,1,2,0.629,4.5,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,0,1,No,0.0,113,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,North America,"Clinical - Age, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages)",,"UPDRS motor scores, UPDRS non-motor scores, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, University of Pennsylvania Smell Identification Test (UPSIT), Beck Depression Inventory (BDI), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cluster I; Cluster II; Cluster III,43; 30; 40,Unknown,No or not sure,113,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
60,Nuclear Imaging Data-Driven Classification of Parkinson's Disease,Totsune,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,Single center,0.0,Clinics or research institutions,0,MDS Clinical Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from neuroimaging studies (such as cortical thickness)",1,0,0,1,1,1,No,0.0,56,No validation was performed,No,45,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Disease staging, Neuroimaging - DaTSCAN, MIBG scintigraphy",0.0,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Medication (types and/or dosages), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN, MIBG H/M ratio; MIBG washout ratio; motor symptom laterality",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale",Neuroimaging data was utilized for clustering purposes but do they do not require quality control (example: DATScan),,,,,,,Clustering,3,early DD; advanced DD; early CC,14; 25; 17,Unknown,No or not sure,56,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
61,Origins of atrophy in Parkinson linked to early onset and local transcription patterns,Maia,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,Yes,1.0,232,Not sure or clearly stated,Yes,117,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America",Neuroimaging - Diffusion Imaging MRI,0.0,"Clinical - Age, Clinical - Gender, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Diffusion Imaging MRI",,"Patient's sex, Patient's age, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Hopkins Verbal Learning Test (HTLV), Benton Visual Retention Test (BVRT), SCOPA-AUT, Geriatric Depression Scale (GDS), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,,"Clustering, Interpretation / Association",,,,,,2,S1; S2,65; 116,Unknown,No or not sure,232,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
62,Parkinson's disease severity clustering based on tapping activity on mobile device,Surangsrirat,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Community or population based,1,Not sure or clearly stated,0,0,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Ethnicity, Education",0,0,0,0,0,1,Not sure or clearly stated,0.0,1851,No validation was performed,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,mPower dataset,North America,Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments,0.0,"Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",,"Patient's sex, Patient's age, Ethnicity, MDS-UPDRS Part I, MDS-UPDRS Part II, Parkinson's Disease Questionnaire 8 Items (PDQ8)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cluster one; Cluster two; Cluster three;,594; 897; 360,Unknown,No or not sure,1851,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
63,Parkinson's Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms,Mu,2017,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Community or population based,1,Not sure or clearly stated,0,0,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,No,0.0,904,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,CLUSTERING: Non-Motor Symptoms Scale (NMSS); global Non-Motor International Longitudinal Study (NILS),Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)","Clustering with different features: Domains Clustering (k-means clustering on the nine non-motor domains, the four cardinal motor signs, and motor complications) and Symptoms Clustering (non-motor symptoms).","The Clinical Impression of Severity Index for PD (CISIPD), Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Non-Motor Symptoms Scale (NNMS), SCOPA-Motor",No neuroimaging data was utilized for clustering purposes,,,,,,,,,"Domains Clustering - D1, D2, D3, D4; Symptoms Clustering - S1, S2, S3, S4, S5, S6","Domains Clustering - D1(428), D2(180), D3(232), D4(64); Symptoms Clustering - S1(456), S2(201), S3(100), S4(73), S5(54), S6(20)",Unknown,No or not sure,904,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
64,Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort,Lawton,2015,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,"The study did provide a follow-up, but did not report this data",The study was cross-sectional or did not inform the follow-up period,0,0,,,"Gender, Ethnicity, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,769,No validation was performed,No,,1,,,,,,,,,Creation,,0,0,0,0,0,1,Oxford Parkinson's Disease Centre (OPDC) cohort study,Europe & Central Asia,"Clinical - Gender, Clinical - Ethnicity, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",,"Patient's sex, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, The Clinical Impression of Severity Index for PD (CISIPD), Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), Beck Depression Inventory (BDI), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,5,"Cluster 1, Cluster 2; Cluster 3; Cluster 4; Cluster 5",195; 179; 160; 145; 90,Unknown,No or not sure,769,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
65,Patterns of cortical thinning in nondemented Parkinson's disease patients,Uribe,2016,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,88,No validation was performed,Yes,31,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,Neuroimaging - Structural or Volumetric MRI,0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages), Neuroimaging - Structural or Volumetric MRI",,"Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Judgment of Line Orientation Test, Digit Span Tests (backward and/or symbol span), Symbol Digit Modalities Test, Benton Visual Retention Test (BVRT), Boston Naming Test (BNT), Geriatric Depression Scale (GDS), Beck Depression Inventory (BDI), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,Clustering,,,,,,,3,The article didn't provide clusters or names for the clusters obtained,30; 29; 29,Unknown,No or not sure,88,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
66,Profiling cognitive and neuropsychiatric heterogeneity in Parkinson's disease,van Balkom,2016,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses",0,0,0,1,1,1,No,0.0,226,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Medication (types and/or dosages)",,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age, Patient's age at onset or diagnosis, UPDRS motor scores, MDS-UPDRS Part II, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Wechsler Adult Intelligence Scale III (WAIS-III), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,The article didn't provide clusters or names for the clusters obtained,86; 15; 46; 79,Unknown,No or not sure,226,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
67,Robust identification of Parkinson's disease subtypes using radiomics and hybrid machine learning,Salmanpour,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Yes,1.0,599,No validation was performed,Yes,163,1,,,,,,Creation,,,,,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Neuroimaging - Radiomics, Neuroimaging - Structural or Volumetric MRI, ",0.0,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Neuroimaging - Radiomics",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Ethnicity, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), Physical attributes (weight, height), Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Digit Span Tests (backward and/or symbol span), Symbol Digit Modalities Test, Benton Visual Retention Test (BVRT), Boston Naming Test (BNT), SCOPA-COG, SCOPA-AUT, SCOPA-Motor, The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Neuropsychiatric Inventory (NPI), Geriatric Depression Scale (GDS), Beck Depression Inventory (BDI)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,Clustering,Clustering,Clustering,,,,Clustering,3,Mild; Moderate; severe,205; 292; 102,Unknown,No or not sure,599,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
68,"Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons",Crowley,2021,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,None of the mentioned data on the PD population was informed by the study,0,0,0,0,0,0,Not sure or clearly stated,0.0,116,58,Yes,65,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,North America,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Diffusion Imaging MRI",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, Mini-Mental State Examination (MMSE), Hopkins Verbal Learning Test (HTLV), Wechsler Adult Intelligence Scale III (WAIS-III), Boston Naming Test (BNT), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,Interpretation / Association,Interpretation / Association,,,Interpretation / Association,,,3,PD Executive; PD Memory; PD Cognitively Well,25; 35; 56,Unknown,No or not sure,116,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,North America,0,0,0,0,0,0,1
69,The association between motor subtypes and psychopathology in Parkinson's disease,Reijnders,2009,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,0,0,0,0,No,0.0,173,173,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Other (pain, fatigue etc), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",,"UPDRS motor scores, UPDRS non-motor scores, Mini-Mental State Examination (MMSE), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Additional clinical scales not listed here were utilized",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,rapid disease progression; young-onset; non-tremor-dominant and psychopathology; tremor-dominant,11; 51; 29; 82,Unknown,No or not sure,173,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
70,The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients,Erro,2013,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,2,The study was cross-sectional or did not inform the follow-up period,0,1,,2.0,"Age, Gender, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,1,1,Yes,1.0,100,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages)",,"Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, MDS-UPDRS Part III, Non-Motor Symptoms Questionnaire (NMSQ), Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), Hospital Anxiety and Depression Scale (HADS)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,Benign Pure Motor; Benign Mixed Motor-Non-Motor; Non-Motor Dominant; Motor Dominant,21; 32; 27; 20,Unknown,No or not sure,100,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
71,The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes,Belvisi,2020,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Not sure or clearly stated,0,MDS Clinical Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,Yes,1.0,100,No validation was performed,Yes,50,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)",0.0,"Clinical - Age, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Neurophysiology - Electroneuromiography, Neurophysiology - Other, Neurophysiology: Transcranial magnetic stimulation; Kinematic recording of motor performance; Somatosensory temporal discrimination threshold (STDT)",,"Patient's sex, Patient's age, Patient's age at onset or diagnosis, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Non-Motor Symptoms Scale (NNMS), Montreal Cognitive Assessment (MoCA), Semantic Fluency Test (e.g. fruits, objects, names etc), Hopkins Verbal Learning Test (HTLV), Benton Visual Retention Test (BVRT), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ)",No neuroimaging data was utilized for clustering purposes,,,,,,,,2,mild motor predominant; diffuse malignant,76; 24,Unknown,No or not sure,100,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
72,The relationships between mild cognitive impairment and phenotype in Parkinson's disease,Szeto,2015,Consensus,1. Identifies Parkinson subtypes,No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales)",0,0,0,1,0,1,No,0.0,209,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Medication (types and/or dosages)",0.0,"Clinical - Age, Clinical - Disease staging, Clinical - Quality of Life",,"Patient's age at onset or diagnosis, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Mini-Mental State Examination (MMSE), Semantic Fluency Test (e.g. fruits, objects, names etc), Wechsler Adult Intelligence Scale III (WAIS-III), The Hoehn & Yahr Scale (or the modified Hoehn & Yahr), Beck Depression Inventory (BDI), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,4,younger age of disease onset; tremor dominant; non-tremor dominant; non-tremor dominant,93; 24; 48; 44,Unknown,No or not sure,209,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
73,The Spectrum of Cognitive Disorders in Parkinson's Disease: A Data-Driven Approach,Dujardin,2013,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,More than one center,1.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,Not sure or clearly stated,0.0,557,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age, UPDRS motor scores, UPDRS non-motor scores, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale",No neuroimaging data was utilized for clustering purposes,,,,,,,,5,Group 1; Group 2; Group 3; Group 4; Group 5;,108; 23-; 72; 133; 14,Unknown,No or not sure,557,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
74,The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease,Aarsland,2009,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Clinics or research institutions,0,Douglas Criteria,1,1,Consecutive or random,1.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Income, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,Yes,1.0,175,175,No,,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc)",,"UPDRS motor scores, Neuropsychiatric Inventory (NPI)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,No/mild symptoms; Mood cluster; Apathy Cluster,158; 10; 4,Unknown,No or not sure,175,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
75,Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease,Zhou,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Convenience,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5,The study was cross-sectional or did not inform the follow-up period,0,2,,5.0,"Age, Gender, Education, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Summarised data from neuroimaging studies (such as cortical thickness)",1,1,1,1,0,1,No,0.0,228,220,Yes,119,1,,,,,,Validation,,,,Creation,1,2,0,1,1,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Neuroimaging - Other Methods (e.g. neuromelanin-sensitive MRI), Neuroimaging - Diffusion Imaging MRI",0.0,"Clinical - Age, Clinical - Gender, Clinical - Ethnicity, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Diffusion Imaging MRI, Neuroimaging - Other Methods (e.g. neuromelanin-sensitive MRI), Omics - Genomics",,"Additional clinical scales not listed here were utilized, Patient's sex, Patient's age, Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Hoehn and Yahr Scale or Modified Hoehn and Yahr Scale, University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), SCOPA-AUT, REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes and a quality control was performed manually,"Clustering, Interpretation / Association","Clustering, Interpretation / Association",,,"Clustering, Interpretation / Association",,Interpretation / Association,2,The article didn't provide clusters or names for the clusters obtained,114; 102,Unknown,No or not sure,228,0,1,1,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
76,Unraveling Parkinson's disease heterogeneity using subtypes based on multimodal data,Albrecht,2022,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,Single center,0.0,Clinics or research institutions,0,Not sure or clearly stated,0,0,Convenience,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,No,0.0,90,No validation was performed,Yes,39,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Other (pain, fatigue etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Functional MRI",0.0,"Clinical - Age, Clinical - Gender, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Features Obtained Through Wearable Sensors or other Technical Instruments, Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Quality of Life, Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - Functional MRI","The article sought to explore how using unimodal data (only clinical, neuroimaging etc) would produce its clusters, however, they thought that multimodal clustering wa superior and, therefore, reported this result","MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA), Wechsler Adult Intelligence Scale IV (WAIS-IV), Hospital Anxiety and Depression Scale (HADS), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,"Clustering, Interpretation / Association","Clustering, Interpretation / Association",,,"Clustering, Interpretation / Association",,,3,motor-cognitive; cognitive dominant; motor dominant,27; 55; 8,Unknown,No or not sure,90,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
77,Parkinson's Disease Non-Motor Subtypes Classification in a Group of Slovenian Patients: Actuarial vs. Data-Driven Approach,Petrijan,2023,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,No,0.0,Single center,0.0,Clinics or research institutions,0,UK Brain Bank Criteria,1,1,Not sure or clearly stated,0.0,The study only utilized baseline data,0.0,0.0,The study did no provide follow-up,The study was cross-sectional or did not inform the follow-up period,0,0,,,"Age, Gender, Education, Family History, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,168,No validation was performed,No,,1,,,,,,,,,,Creation,0,0,0,0,0,1,No additional datasets aside from the above were utilized,Europe & Central Asia,"Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages), Clinical - Other (pain, fatigue etc)",,"Additional clinical scales not listed here were utilized, Patient's age, Non-Motor Symptoms Scale (NNMS), Montreal Cognitive Assessment (MoCA), REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,Cortical; limbic; brainstem,38; 48; 82,Unknown,No or not sure,168.0,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,Europe & Central Asia,0,0,0,0,1,0,0
78,Brain network centrality and connectivity are associated with clinical subtypes and disease progression in Parkinsons disease,Chen,2024,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Not sure or clearly stated,0.0,Single center,0.0,Clinics or research institutions,0,MDS Clinical Criteria,1,1,Not sure or clearly stated,0.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,2.75,0.92,2,1,0.92,2.75,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,Not sure or clearly stated,0.0,92,Not sure or clearly stated,No,38,1,,,,,,,,,,"Creation, Validation",1,1,1,1,0,1,No additional datasets aside from the above were utilized,"East Asia & Pacific (China, Japan, Australia)","Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Other (pain, fatigue etc)",0.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties)","Clusters in Strategy 1: 92 PD participants divided into mild PD (63) and moderate PD (29) |
Clusters in Strategy 2: in addition to the strategy 1, the mild PD cluster (63) was subdived into mild motor-predominant PD (36) and  mild-diffuse PD (27). Finally, in total, it was considered three different clinical phenotypes of PD patients","Additional clinical scales not listed here were utilized, Patient's age at onset or diagnosis, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Digit Span Tests (backward and/or symbol span), Symbol Digit Modalities Test, Boston Naming Test (BNT), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,Interpretation / Association,,,,3,mild motor-predominant PD; mild-diffuse PD; moderate PD,36; 27; 29,Unknown,No or not sure,92.0,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,"East Asia & Pacific (China, Japan, Australia)",0,0,1,0,0,0,0
79,Progression subtypes in Parkinsons disease identified by a data-driven multi cohort analysis,Hhnel,2024,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,"UK Brain Bank Criteria, Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI)",1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,7,1,2,2,1.0,7.0,"Age, Gender, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,0,1,1,0,1,Yes,1.0,1124,Not sure or clearly stated,No,,1,,,,,,"Creation, Validation",,,,"Creation, Validation",1,1,1,2,0,2,Validation: ICEBERG cohort study; Luxembourg Parkinsons Study,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties),",1.0,"Clinical - Age, Clinical - Gender, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication Response, Clinical - Other (pain, fatigue etc), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - DaTSCAN",,"MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, University of Pennsylvania Smell Identification Test (UPSIT), Non-Motor Symptoms Questionnaire (NMSQ), Montreal Cognitive Assessment (MoCA), SCOPA-AUT, REM-Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Parkinson's Disease Questionnaire 39 Items (PDQ39), Other clinical scales (not present in this form)",No neuroimaging data was utilized for clustering purposes,,,,,,,Interpretation / Association,2,Fast-progressing; Slow-progressing,259; 855,Unknown,No or not sure,1124.0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
80,Dopa Responsiveness in Parkinson's Disease,Gandhi,2024,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,0,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,5.9,76.6,2,2,76.6,5.9,"Age, Gender, Education, Age at disease onset, Disease duration (years) or staging (such as Hoehn & Yahr and Schawb and England scales), Physical Attributes (weight, height etc), Medication Doses, Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms)",0,1,1,1,1,1,No,0.0,336,No validation was performed,No,,1,,,,,,Creation,,,,No additional datasets aside from the above were utilized,0,0,0,0,0,1,No additional datasets aside from the above were utilized,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America","Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Medication Response",1.0,"Clinical - Gender, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Age at disease onset, Clinical - Disease staging, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Motor Complications (dyskinesia, OFF periods, dystonia, motor fluctuations), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Clinical - Medication (types and/or dosages)",,"Patient's sex, Patient's age at onset or diagnosis, Physical attributes (weight, height), Levodopa Equivalent Daily Dosage (LEDD) or Medication Usage, UPDRS motor scores, UPDRS non-motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, MDS-UPDRS Part IV, Montreal Cognitive Assessment (MoCA)",No neuroimaging data was utilized for clustering purposes,,,,,,,,3,striking; excellent; modest,29; 110; 197,Unknown,No or not sure,336.0,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
81,Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression,Fereshtehnejad,2017,Consensus,"1. Identifies Parkinson subtypes, 2. Uses unsupervised learning or a data driven approach to generate the clusters (subtypes)",No Exclusion criteria checked,Not clearly stated,1,Yes,1.0,More than one center,1.0,Community or population based,1,Clinical Diagnosis + Positive Dopamine Transporter (DAT) SPECT (PPMI),1,1,Consecutive or random,1.0,The study utilized longitudinal clinical data for clustering and/or association or interaction analyses,1.0,1.0,32.8,1,2,2,1.0,32.8,"Age, Gender, Ethnicity, Education, Family History, Age at disease onset, Genetic Status (monogenic PD, polygenic risk score), Summarised data from clinical scales (such as mean MDS-UPDRS scores, number of non-motor symptoms), Summarised data from neuroimaging studies (such as cortical thickness), Biomarker's profile (results from biomarker tests)",1,0,0,0,1,1,Yes,1.0,421,No validation was performed,No,,1,,,,,,Creation,,,,No additional datasets aside from the above were utilized,0,0,0,0,0,1,,"Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, North America"," Clinical - Age, Clinical - Vital Signs or Neurologic Examination Findings, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Omics - Genomics",0.0,"Clinical - Age at disease onset, Clinical - Gender, Clinical - Ethnicity, Clinical - Motor Features Obtained Through Rating Scales (tremor), Clinical - Motor Features Obtained Through Rating Scales (bradykinesia), Clinical - Motor Features Obtained Through Rating Scales (rigidity), Clinical - Motor Features Obtained Through Rating Scales (gait and/or posture), Clinical - Motor Features Obtained Through Rating Scales (speech), Clinical - Cognition (memory, attention, executive, visuospatial memory etc), Clinical - Neuropsychiatric (anxiety, depression, impulsivity, delusions, hallucinations etc), Clinical - Sleep (REM sleep behavior disorder, insomnia, daytime sleepiness), Clinical - Anosmia or Hyposmia (absence or loss of the capability to smell), Clinical - Autonomic (gastroparesis, constipation, orthostatic hypotension, urinary incontinence, sexual difficulties), Biomarkers (uric acid, LDL, tryglicerides, neurofilament light [Nfl], tau, SAA etc), Neuroimaging - Structural or Volumetric MRI, Neuroimaging - DaTSCAN","Various measures were tested to estimate the optimal number of clusters. Of 24 solutions, 10 suggested two clusters, and seven suggested three clusters . Hartigans rule (value = 6.03 for three clusters). Ultimately, we prioritized the three-cluster solution because of a better balanced data distribution as well as clin- ical relevance. Furthermore, to check the stability of the clustering, we randomly half-split the study population and the same clustering method was repeated. This procedure was repeated 1000 times and the case mem- berships were cross-checked with that of the original cluster- ing each time. ","Patient's sex, Patient's age, Vital signs (blood pressure [including orthosthatic hypotension tests], cardiac frequency etc), UPDRS motor scores, MDS-UPDRS Part I, MDS-UPDRS Part II, MDS-UPDRS Part III, University of Pennsylvania Smell Identification Test (UPSIT), State-Trait Anxiety Inventory for Adults (STAI), Montreal Cognitive Assessment (MoCA), SCOPA-AUT, The Schwab and England ADL (Activities of Daily Living) scale, State-Trait Anxiety Inventory (STAI), Questionnaire for Impulsive-Compulsive Disorders in Parkinsons Disease (QUIP), Epworth Sleepiness Scale (ESS)",Neuroimaging data was utilized for clustering purposes but no quality control was mentioned,Interpretation / Association, Interpretation / Association,,,,, Interpretation / Association,3,Diffuse malignant; Intermediate; mild motor,221; 162; 38,Yes,Yes,421.0,0,1,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,"Europe & Central Asia, North America",1,1,0,0,1,0,1
